- Infants aged <8 months born during or entering their first RSV season are recommended to receive one dose of nirsevimab (50 mg for infants <5 kg and 100 mg for infants ≥ 5 kg).
- Children aged 8-19 months who are at increased risk of severe RSV disease and entering their second RSV season are recommended to receive one dose of nirsevimab (200 mg).
- Adults 60 years of age and older may receive a single dose of RSV vaccines, using shared clinical decision-making.
- Talk with your doctor or care team about vaccine options right for you.
